Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biopharmaceutical company focused on fibrosis-first therapies, will participate in the H.C. Wainwright 27th Annual Global Investment Conference. The company's management will deliver their presentation on September 10, 2025, at 12:30 p.m. ET.
Investors can register in advance for the presentation webcast, which will be available on Gyre's website Events and Presentations page. A replay will be accessible after the live session.
Gyre Therapeutics (Nasdaq: GYRE), azienda biofarmaceutica in fase commerciale focalizzata su terapie che puntano alle fibrosi, parteciper脿 alla H.C. Wainwright 27th Annual Global Investment Conference. Il management terr脿 la presentazione il 10 settembre 2025 alle 12:30 ET.
Gli investitori possono registrarsi in anticipo per il webcast della presentazione, che sar脿 disponibile nella pagina Eventi e Presentazioni del sito di Gyre. Dopo la diretta sar脿 possibile rivedere la registrazione.
Gyre Therapeutics (Nasdaq: GYRE), una compa帽铆a biofarmac茅utica en fase comercial centrada en terapias para la fibrosis, participar谩 en la H.C. Wainwright 27th Annual Global Investment Conference. La direcci贸n de la compa帽铆a presentar谩 el 10 de septiembre de 2025 a las 12:30 p.m. ET.
Los inversores pueden registrarse previamente para el webcast de la presentaci贸n, que estar谩 disponible en la p谩gina Eventos y Presentaciones del sitio web de Gyre. Tras la emisi贸n en directo se podr谩 acceder a la repetici贸n.
Gyre Therapeutics (Nasdaq: GYRE), 靹湢歃� 欷戩嫭 旃橂氩曥棎 欤茧牓頃橂姅 靸侅梾 雼硠鞚� 氚旍澊鞓れ牅鞎届偓搿滌劀 H.C. Wainwright 27th Annual Global Investment Conference鞐� 彀戈皜頃╇媹雼�. 須岇偓 瓴届榿歆勳潃 2025雲� 9鞗� 10鞚� 鞓ろ泟 12:30(霃欕秬鞁滉皠)鞐� 氚滍憸毳� 歆勴枆頃╇媹雼�.
韴瀽鞛愲摛鞚� 氚滍憸 鞗轨簮鞀ろ姼鞐� 靷爠 霌彪頃� 靾� 鞛堨溂氅�, 鞗轨簮鞀ろ姼電� Gyre 鞗轨偓鞚错姼鞚� 鞚措菠韸� 氚� 頂勲爤鞝犿厡鞚挫厴 韼橃澊歆�鞐愳劀 鞝滉车霅╇媹雼�. 霛检澊敫� 膦呺 頉勳棎電� 鞛嫓觳澊 臧�電ロ暕雼堧嫟.
Gyre Therapeutics (Nasdaq: GYRE), soci茅t茅 biopharmaceutique en phase commerciale ax茅e sur des th茅rapies ciblant les fibroses, participera 脿 la H.C. Wainwright 27th Annual Global Investment Conference. La direction de l'entreprise pr茅sentera le 10 septembre 2025 脿 12h30 ET.
Les investisseurs peuvent s'inscrire 脿 l'avance pour le webdiffusion de la pr茅sentation, qui sera disponible sur la page 脡v茅nements et Pr茅sentations du site web de Gyre. Un replay sera accessible apr猫s la diffusion en direct.
Gyre Therapeutics (Nasdaq: GYRE), ein kommerziell t盲tiges Biopharmaunternehmen mit Fokus auf fibroseorientierte Therapien, wird an der H.C. Wainwright 27th Annual Global Investment Conference teilnehmen. Die Gesch盲ftsf眉hrung wird ihre Pr盲sentation am 10. September 2025 um 12:30 Uhr ET halten.
Investoren k枚nnen sich im Voraus f眉r das Pr盲sentations-Webcast registrieren, das auf der Seite Veranstaltungen und Pr盲sentationen der Gyre-Website verf眉gbar sein wird. Nach der Live-脺bertragung steht ein Replay zur Verf眉gung.
- None.
- None.
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (鈥淕yre鈥�) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 at 12:30 p.m. ET.
To register in advance for the presentation webcast, sign up .
The live webcast of the presentation will be also available on the page of Gyre鈥檚 website. A webcast replay will also be accessible following the live session.
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States Gyre鈥檚 strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People鈥檚 Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY庐, and development programs for F573, F528, and F230.
For Investors:
David Zhang
Gyre Therapeutics
[email protected]
FAQ
When is Gyre Therapeutics (GYRE) presenting at the H.C. Wainwright Conference?
How can investors access Gyre Therapeutics' (GYRE) H.C. Wainwright conference presentation?
What is Gyre Therapeutics' (GYRE) main business focus?
Where can investors find the replay of Gyre Therapeutics' (GYRE) H.C. Wainwright presentation?
